Autres langues AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:08 14/05/2026			Varia. 5j.	Varia. 1 janv.
13 740,00 ^GBX	-0,19%		+3,20%	-0,36%

17:05	Les actions européennes négociées aux États-Unis sous forme d'ADR s'inscrivent en hausse lors de la séance de jeudi	MT
12:14	L'immunothérapie d'AstraZeneca contre le cancer de l'estomac autorisée par le NHS	AN

Autres langues

17:05	European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
13:02	Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
12:14	AstraZeneca immunotherapy for stomach cancer green lit for NHS use
10:09	AstraZeneca's bladder cancer drug yields encouraging test results
09:44	AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial
08:59	AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial
08:37	AstraZeneca says no new safety signals for Imfinzi with or without Imjudo plus Enfortumab Vedotin
08:23	AstraZeneca Combo Therapy Shows Improved Event-free, Overall Survival in Bladder Cancer
08:07	AstraZeneca : Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
13/05	AstraZeneca tiene una trayectoria de crecimiento creíble más allá de 2030 -- Market Talk
13/05	AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making
13/05	Astrazeneca Expands AI Partnership With Owkin Under Three-Year Licensing Deal
13/05	Owkin Enters License Agreement With AstraZeneca
12/05	AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism
12/05	AstraZeneca hails phase-3 trial results for hypoparathyroidism drug
12/05	AstraZeneca : Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
06/05	Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly
05/05	Citi cuts Severn Trent and United Utilities
05/05	Pharmabranche: Warkens Sparpaket bedroht Arznei-Standort
04/05	Global pharma companies that have publicly announced Trump drug pricing agreements
03/05	AstraZeneca invests £300 million in UK drug development sites